The Peptide Evidence Gap: How 59+ Compounds Score on Human Evidence
Key Takeaways
- 59 compounds graded across peptides and GLP-1 agents
- 12 are FDA-approved drugs; 47 are not approved, withdrawn, or compounding-restricted
- 34 of 59 (58%) have at least one randomized human trial (Grade A or B)
- 11 compounds have preclinical-only or no evaluated evidence (Grade D / NE)
Grade distribution
| Grade | Count | Share |
|---|---|---|
| Grade A: Approved and proven | 12 | 20% |
| Grade B: Human evidence, not approved for this use | 22 | 37% |
| Grade C: Preliminary or limited human evidence | 14 | 24% |
| Grade D: Preclinical or anecdotal only | 11 | 19% |
| Not evaluated | 0 | 0% |
| Total | 59 | 100% |
Of 59 compounds graded, 12 are FDA-approved prescription drugs with established efficacy and safety data. The remaining 47 are sold or promoted despite lacking FDA approval, including compounds in restricted-compounding categories.
Only 34 compounds (58%) have evidence from randomized human trials, earning Grade A or B. The majority are supported by observational data, case series, or no human evidence at all.
11 compounds carry a Grade D or are not yet evaluated, meaning their evidence base is preclinical (animal or cell studies) or absent. These are sold despite no completed human efficacy data.
Methodology: how grades are assigned
Last updated: 2026-06-02